On 23 July 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Latuda. The marketing authorisation holder for this medicinal product is Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Latuda is indicated for the treatment of schizophrenia in adults
aged 18 years and adolescent aged 13 years and over.
Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
1 New text in bold, removed text as strikethrough
|Agency product number||
|International non-proprietary name (INN) or common name||
|Date opinion adopted||